Combined with anti-PD-1, SHP099 or TNO155 enhance CD8+ T cell activation and tumor infiltration while reducing overall immune cell infiltration and altering tumor-associated macrophage composition (115, 117). The gene discussed is CD8A; the disease is neoplasm.